OBJECTIVE To mine the risk signals associated with erectile dysfunction （ED） related to antihypertensive drugs based on real-world data， and to provide a reference for the safe clinical use and risk monitoring of these drugs.METHODS Reports of ED associated with 15 target antihypertensive drugs were extracted from the US FDA Adverse Event Reporting System （FAERS） database， covering the period from the first quarter of 2004 to the first quarter of 2026. Three proportional disproportionality measures （reporting odds ratio， proportional reporting ratio， and empirical Bayesian geometric mean） were used to mine the risk signals for ED associated with various antihypertensive drugs， and stratified analyses were performed based on patient age and body weight.RESULTS A total of 997 ED reports associated with 15 antihypertensive drugs were included. The majority were male patients （931 reports）， with age concentrated in the 18 to ＜65 years group （511 reports）， body weight in the 50 to ＜100 kg group （366 reports）， and reporters predominantly consumers/patients （497 reports）. The top three drugs by number of reports were amlodipine （413 reports）， metoprolol （133 reports）， and valsartan （82 reports）； the overall demographic distribution characteristics of reports associated with each drug were similar. Positive signals were detected for 8 drugs， including amlodipine and metoprolol. ED associated with atenolol， candesartan， metoprolol， hydrochlorothiazide， and losartan mostly occurred within 30 days after medication； ED associated with valsartan and perindopril mostly occurred over 360 days after medication； and the onset time of amlodipine-associated ED was evenly distributed across all time periods. There were a total of 835 serious reports， with calcium channel blockers （CCBs） accounting for the highest proportion （44.0%） and angiotensin-converting enzyme inhibitors for the lowest （3.7%）. The intensity of risk signals for amlodipine-associated ED increased with advancing age and higher body weight， while the signals for metoprolol were most pronounced in individuals aged 45 to ＜60 years and weighing≥100 kg； positive signals for valsartan were observed only in individuals aged≥60 years and those weighing 50 to ＜75 kg or ≥100 kg.CONCLUSIONS Reports of ED associated with antihypertensive drugs exhibit significant heterogeneity across drug types and differences in the distribution of onset times； CCBs have the highest proportion of serious reports； and the relationship between ED risk signals associated with amlodipine， metoprolol， and valsartan and age and body weight also shows marked heterogeneity.

Objective:To optimize the processing technology of vinegar-Corni Fructus using Box Behnken design and entropy weight method.Methods:The optimal processing parameters of vinegar-Corni Fructus were optimized by Box-Behnken design. 5-Hydroxymethylfurfural, Nuxaside, Monosanthin, and appearance character were used as comprehensive evaluation indexes. The entropy weight method was used to calculate the weights of each index, taking Design Expert 12.0 for data analysis.Results:The optimal process for vinegar-Corni Fructus as follow: The ratio of excipients was 15%, the simmering time was 2 h, and the steaming time was 8 h.Conclusion:The optimal vinegar-Corni Fructus processing is stable and feasible, which can be used for the production of processed prescriptions.

OBJECTIVE:To establish a HPLC method for the content determination of baicalin in Pneumonia I mixture.METHODS:The assaying was conducted on a ODS C 18 column with methol-0.06%H 3 PO 4 (43∶57)as mobile phase,the detection wavelength was278nm,the column temperature was25℃and the flow rate was1.0ml/min.RESULTS:The linear concentration range of baicalin was0.1875?g～1.5?g(r=0.9998)with average recovery rate at99.63%(RSD=1.00%,n=6).CONCLUSION:This method is simple,accurate and reproducible,and it can be used for the quality control of baicalin.